Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Conference Call November 6, 2024 8:30 AM ET
Company Participants
Andrew Faughnan - VP, IR
Bradley Campbell - President and CEO
Sebastien Martel - Chief Business Officer
Jeff Castelli - Chief Development Officer
Simon Harford - CFO
Ellen Rosenberg - Chief Legal Officer
Conference Call Participants
Ritu Baral - TD Cowen
Anupam Rama - JP Morgan
Tazeen Ahmad - Bank of America Securities
Ellie Merle - UBS
Joe Schwartz - Leerink Partners
Dae Gon Ha - Stifel
Dennis Ding - Jefferies
Kristen Kluska - Cantor Fitzgerald
Michael Riad - Morgan Stanley
Gil Blum - Needham & Company
Salveen Richter - Goldman Sachs
Operator
Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Third Quarter 2024 Financial Results Conference Call and Webcast. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.
Andrew Faughnan
Good morning. Thank you for joining our conference call to discuss Amicus Therapeutics' third quarter 2024 financial results and corporate highlights. Leading today's call we have Bradley Campbell, President and Chief Executive Officer; Sebastien Martel, Chief Business Officer; Dr. Jeff Castelli, Chief Development Officer; and Simon Harford, Chief Financial Officer. Joining for Q&A is Ellen Rosenberg, Chief Legal Officer. As referenced on Slide 2, we might make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us and any of our plans will be achieved. Any or all the forward-looking statements made on this call may turn out to be wrong and can be